An important achievement has been achieved by the BIOGENERA Research Team regarding the scientific publication of an article in the prestigious international journal “Pharmaceutics.” The article titled “Precision Anti-Cancer Medicines by Oligonucleotide Therapeutics in Clinical Research Targeting Undruggable Proteins and Non-Coding RNAs” is about the importance of precision medicine in oncology. In particular, the study highlights the importance of oligonucleotides as a new class of targeted biotechnology drugs for cancer treatment that can target cancer cells through drug targets for which traditional pharmacological approaches had not been effective.
The article also describes BIOGENERA’s new anti-tumor drug BGA002, which is generated through the MyGeneraTM platform and belongs to this new class of oligonucleotide biotech drugs.
article link
https://pubmed.ncbi.nlm.nih.gov/35890348/
Download the article
Bartolucci et al. 2022 pharmaceutics.
